Michael Barbella, Managing Editor03.25.21
The U.S. Food and Drug Administration (FDA) has granted clearance to Neurolief's Relivion system.
Relivion is the first non-invasive multi-channel brain neuromodulation system for at home treatment of acute migraine, a debilitating neurological disease impacting 39 million people and resulting in 1.2 million emergency department visits annually.
The FDA marketing clearance is based on the results of a multi-center, prospective, randomized, double-blind, placebo-controlled clinical study. Forty-six percent (46%) of the patients in the active group reached complete pain freedom compared to only 11.8 percent of patients in the control group. Seventy five percent of patients in the active group reached complete freedom of “Most Bothersome Symptom” (MBS, which is defined as either phonophobia, photophobia, or nausea), within two hours following treatment, compared to 46.7 percent in the control group. Complete freedom of migraine symptoms (freedom from pain as well as freedom from MBS) at two hours after treatment was significantly higher in the active group than in the control group (47.2 percent vs. 11.1 percent). Pain relief was also significantly higher in the active group than in the control group at two hours after treatment (60 percent vs. 37 percent). No serious adverse events were reported. Patients started using either the Relivion or a “placebo” device with lower treatment intensity, at the onset of their migraine episode for up to one hour. Patients were able to treat several migraine episodes during the course of the trial. The study, RIME, was conducted at leading clinical centers in the United States and Israel and evaluated the safety and efficacy of the device with 131 patients who met the International Classification of Headache Disorders (ICHD-3) criteria of migraine with or without aura.
“The FDA clearance of the Relivion non-invasive device is an important event for those suffering from migraines, as it is the only neuromodulation technology thus far that has demonstrated statistically significant efficacy in providing complete freedom of migraine symptoms within 2 hours after treatment, in a sham-controlled clinical trial,” said Stewart J. Tepper, M.D., professor of Neurology at the Geisel School of Medicine at Dartmouth, who was the principal investigator on the pivotal international trial. “Patients will now have access to a highly effective, easy-to-use, non-invasive, and drug free therapeutic option that will help them regain control of their lives.”
Relivion, which is worn as a headset, offers precise, personalized care to patients by delivering unparalleled stimulation to six branches of the occipital and trigeminal nerves via three adaptive output channels. This allows for the release of neurotransmitters in the brainstem and modulation of brain networks associated with control of pain.
“This is a major milestone both for Neurolief and the migraine community. Relivion® offers a new paradigm for doctors treating migraine patients, reducing the dependence on pharmaceutical products and invasive procedures while keeping doctors informed of the patient’s progress,” said Chris Richardson, Neurolief’s board chairman. “It also demonstrates our commitment to becoming the leader in neuromodulation therapy, and allows a springboard to advance this technology in the future for other neurological and neuropsychiatric disorders.”
Relivion previously received CE Mark certification, which indicates it conforms with health, safety, and environmental protection standards for products sold in Europe, as a treatment device for migraine, and is in preparation for the market launch. Last year, Relivion DP for the treatment of major depressive disorder received Breakthrough Device designation from the FDA. Neurolief plans to file the application for major depressive disorder by 2022. Other neurological and neuropsychiatric indications, including ADHD and insomnia, are also being explored.
Migraine is a common neurological disease affecting 39 million men, women and children in the United States, resulting in 1.2 million emergency department visits each yeari. Causing severe throbbing or pulsing pain, migraines are headaches that are often accompanied by nausea, vomiting, mood changes, fatigue and extreme sensitivity to light, sound or smell, among other potential symptoms. Prior to a migraine attack, approximately half of all patients experience a phase called prodrome, which may include constipation, low mood or fatigue, among other symptoms, and approximately 20 percent of all patients experience an aura phaseii, which involves visual, sensory, motor or verbal disturbances that may be disabling. More than 90 percent of sufferers are unable to work or function normally during their migraine, and while most migraines last several hours, they can persist for days.
Relivion is the first non-invasive multi-channel brain neuromodulation system for at home treatment of acute migraine, a debilitating neurological disease impacting 39 million people and resulting in 1.2 million emergency department visits annually.
The FDA marketing clearance is based on the results of a multi-center, prospective, randomized, double-blind, placebo-controlled clinical study. Forty-six percent (46%) of the patients in the active group reached complete pain freedom compared to only 11.8 percent of patients in the control group. Seventy five percent of patients in the active group reached complete freedom of “Most Bothersome Symptom” (MBS, which is defined as either phonophobia, photophobia, or nausea), within two hours following treatment, compared to 46.7 percent in the control group. Complete freedom of migraine symptoms (freedom from pain as well as freedom from MBS) at two hours after treatment was significantly higher in the active group than in the control group (47.2 percent vs. 11.1 percent). Pain relief was also significantly higher in the active group than in the control group at two hours after treatment (60 percent vs. 37 percent). No serious adverse events were reported. Patients started using either the Relivion or a “placebo” device with lower treatment intensity, at the onset of their migraine episode for up to one hour. Patients were able to treat several migraine episodes during the course of the trial. The study, RIME, was conducted at leading clinical centers in the United States and Israel and evaluated the safety and efficacy of the device with 131 patients who met the International Classification of Headache Disorders (ICHD-3) criteria of migraine with or without aura.
“The FDA clearance of the Relivion non-invasive device is an important event for those suffering from migraines, as it is the only neuromodulation technology thus far that has demonstrated statistically significant efficacy in providing complete freedom of migraine symptoms within 2 hours after treatment, in a sham-controlled clinical trial,” said Stewart J. Tepper, M.D., professor of Neurology at the Geisel School of Medicine at Dartmouth, who was the principal investigator on the pivotal international trial. “Patients will now have access to a highly effective, easy-to-use, non-invasive, and drug free therapeutic option that will help them regain control of their lives.”
Relivion, which is worn as a headset, offers precise, personalized care to patients by delivering unparalleled stimulation to six branches of the occipital and trigeminal nerves via three adaptive output channels. This allows for the release of neurotransmitters in the brainstem and modulation of brain networks associated with control of pain.
“This is a major milestone both for Neurolief and the migraine community. Relivion® offers a new paradigm for doctors treating migraine patients, reducing the dependence on pharmaceutical products and invasive procedures while keeping doctors informed of the patient’s progress,” said Chris Richardson, Neurolief’s board chairman. “It also demonstrates our commitment to becoming the leader in neuromodulation therapy, and allows a springboard to advance this technology in the future for other neurological and neuropsychiatric disorders.”
Relivion previously received CE Mark certification, which indicates it conforms with health, safety, and environmental protection standards for products sold in Europe, as a treatment device for migraine, and is in preparation for the market launch. Last year, Relivion DP for the treatment of major depressive disorder received Breakthrough Device designation from the FDA. Neurolief plans to file the application for major depressive disorder by 2022. Other neurological and neuropsychiatric indications, including ADHD and insomnia, are also being explored.
Migraine is a common neurological disease affecting 39 million men, women and children in the United States, resulting in 1.2 million emergency department visits each yeari. Causing severe throbbing or pulsing pain, migraines are headaches that are often accompanied by nausea, vomiting, mood changes, fatigue and extreme sensitivity to light, sound or smell, among other potential symptoms. Prior to a migraine attack, approximately half of all patients experience a phase called prodrome, which may include constipation, low mood or fatigue, among other symptoms, and approximately 20 percent of all patients experience an aura phaseii, which involves visual, sensory, motor or verbal disturbances that may be disabling. More than 90 percent of sufferers are unable to work or function normally during their migraine, and while most migraines last several hours, they can persist for days.
